Barclays Maintains an 'Overweight' on LINN Energy (LINE); First Quarter Update
Get Alerts LINE Hot Sheet
Price: $41.46 -0.74%
Rating Summary:
8 Buy, 11 Hold, 10 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
8 Buy, 11 Hold, 10 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Barclays maintains an 'Overweight' on LINN Energy (NASDAQ: LINE), PT $45.
Barclays analyst says, "We believe LINE has assembled a large inventory of liquids projects that could support visible distribution growth over the next several years...We are revising our FY11 EBITDA/DCF per unit estimates to $5.65/$3.55 from $5.30/$3.40 and our FY12 EBITDA/DCF per unit estimates to $5.90/$3.75 from $5.80/$3.90. Our current distributable cash flow estimates imply coverage ratios of 1.3x in 2011 and 1.4x in 2012 based on the current annualized distribution of $2.64. Assuming a 10% increase in the distribution to $2.90 per unit, we estimate the company would still be able to maintain a coverage ratio of 1.3x in 2012."
For more ratings news on LINN Energy click here and for the rating history of LINN Energy click here.
Shares of LINN Energy closed at $40.38 yesterday.
Barclays analyst says, "We believe LINE has assembled a large inventory of liquids projects that could support visible distribution growth over the next several years...We are revising our FY11 EBITDA/DCF per unit estimates to $5.65/$3.55 from $5.30/$3.40 and our FY12 EBITDA/DCF per unit estimates to $5.90/$3.75 from $5.80/$3.90. Our current distributable cash flow estimates imply coverage ratios of 1.3x in 2011 and 1.4x in 2012 based on the current annualized distribution of $2.64. Assuming a 10% increase in the distribution to $2.90 per unit, we estimate the company would still be able to maintain a coverage ratio of 1.3x in 2012."
For more ratings news on LINN Energy click here and for the rating history of LINN Energy click here.
Shares of LINN Energy closed at $40.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hims and Hers (HIMS) PT Lowered to $35 at Barclays
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share